Are you tired of being caught off-guard by patients asking for a new medication on the market that you’ve never heard of? Well, we’ve got some good news…
NICA publishes quarterly pipeline reports! We have two late-stage pipeline reports, one for IV/injectable medications and one for IV/inj. biosimilars. Both reports capture “late-stage” products, including those: in Phase III clinical trials, that have been filed for approval, that have been approved, and that have come to market. The late-stage IV/inj. report captures both primary and secondary indications. We also release a change summary with each report to capture the changes since the previous quarter’s report.
How could it get any better, you ask? Well, NICA paid-members get a discount!
So, subscribe to the pipeline reports, sit back, and stay up-to-speed on new therapeutic options you could be administering in your infusion suite!
This sounds like a wonderful resource!! When you state “come to the market”, are you speaking globally or just the U.S.?
Viewing 2 posts - 1 through 2 (of 2 total)
You must be logged in to reply to this topic.
National Infusion Center Association is a 501(c)(3) nonprofit patient advocacy organization working to provide a national voice for office-based Infusion Centers across disease specialties in the interest of improving patient access to high-quality, cost-effective care.